Key strengths include a differentiated technology portfolio centered on graphene‑based coatings, a potentially strategic high‑purity graphite deposit, and an asset‑light, partnership‑oriented business model that emphasizes intellectual property over heavy fixed investment. The company has moderate leverage and has been able to raise financing to support operations. A focused strategy around ZenGUARD, Albany graphite, and aptamer‑based diagnostics provides clearer priorities than a more scattered R&D approach.

The main risks are financial and execution‑related. Zentek currently records minimal revenue and sizable recurring losses, with strong negative operating and free cash flow that require ongoing external funding. Short‑term liquidity is tight relative to obligations, and large accumulated losses highlight the long path to date without sustained profitability. On the operating side, success depends on securing regulatory approvals, scaling production, proving real‑world performance, and achieving meaningful market adoption in the face of established competitors and fast‑moving alternative technologies.

The outlook hinges on whether Zentek can transition from being primarily an R&D organization to a commercially scaled technology provider. If ZenGUARD gains broad regulatory acceptance and adoption, if the Albany graphite project proves economically attractive, and if Triera’s diagnostics platform secures compelling partnerships, the financial profile could change materially over time. Until there is clear evidence of sustained revenue growth and improving cash generation, however, Zentek is likely to remain a high‑uncertainty, development‑stage company with outcomes that depend heavily on execution and external approvals.